Filing Flows › Entrada Therapeutics (TRDA) › Q2 2026 › vs Q1 2026
Entrada Therapeutics (TRDA) Q2 2026 vs Q1 2026 (quarter over quarter)
Entrada Therapeutics's revenue rose $23K (+3%) from $875K in Q1 2026 to $898K in Q2 2026.
Entrada Therapeutics, Q2 2026: revenue $898K (-54% year over year), net loss $42.8M, operating cash flow −$32.5M. The chart draws each line against Q1 2026, the increases inside each band.
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $898K | $875K | $23K | +3% |
| Other income, net | $2.2M | $2.6M | −$389K | -15% |
| Net loss | $42.8M | $39.7M | $3.0M | +8% |
| Costs & expenses | $45.9M | $43.2M | $2.7M | +6% |
| Operating costs | $45.9M | $43.2M | $2.7M | +6% |
| Income tax | $35K | $38K | −$3K | -8% |
| Research & development | $35.4M | $33.1M | $2.3M | +7% |
| General & admin | $10.5M | $10.1M | $368K | +4% |
| Operating cash sources | $42.8M | $39.7M | $3.0M | +8% |
| Depreciation | $800K | $805K | −$5K | -0.6% |
| Share-based compensation | $5.2M | $4.7M | $406K | +9% |
| Working capital & other | $4.3M | −$7.5M | $11.9M | — |
| Cash used in operations | $32.5M | $41.7M | −$9.2M | -22% |
| Net loss absorbed | $42.8M | $39.7M | $3.0M | +8% |
Questions
How much did Entrada Therapeutics's revenue grow quarter over quarter in Q2 2026?
Entrada Therapeutics's revenue rose $23K (+3%) from $875K in Q1 2026 to $898K in Q2 2026.